Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 | 2015-03-31 | 2014-03-31 | 2013-03-31 | 2012-03-31 | 2011-03-31 | 2010-03-31 | 2009-03-31 | 2008-03-31 | 2007-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $411.0B | $403.4B | $359.1B | $309.0B | $276.7B | $264.0B | $238.2B | $231.1B | $214.3B | $208.4B | $198.5B | $190.9B | $179.0B | $137.6B | $122.5B | $122.7B | $112.1B | $108.7B | $106.6B | $101.7B | $93.0B |
| Bruttoergebnis | $15.0B | $14.6B | $12.5B | $12.2B | $11.9B | $12.6B | $11.6B | $11.4B | $10.8B | $10.4B | $10.7B | $10.9B | $10.9B | $8.0B | $6.8B | $6.4B | $6.0B | $5.7B | $5.4B | $5.0B | $4.3B |
| Bruttomarge % | 3.6% | 3.6% | 3.5% | 4.0% | 4.3% | 4.8% | 4.9% | 4.9% | 5.0% | 5.0% | 5.4% | 5.7% | 6.1% | 5.8% | 5.5% | 5.2% | 5.3% | 5.2% | 5.1% | 4.9% | 4.7% |
| Betriebsergebnis (EBIT) | $6.8B | $6.5B | $4.4B | $3.9B | $4.5B | $2.7B | $3.5B | $3.0B | $3.1B | $2.9B | $3.4B | $3.9B | $3.5B | $2.6B | $2.4B | $2.4B | $2.1B | $2.0B | $1.7B | $1.5B | $1.3B |
| Operative Marge % | 1.6% | 1.6% | 1.2% | 1.3% | 1.6% | 1.0% | 1.5% | 1.3% | 1.4% | 1.4% | 1.7% | 2.0% | 2.0% | 1.9% | 2.0% | 1.9% | 1.9% | 1.8% | 1.6% | 1.5% | 1.4% |
| Jahresüberschuss | $4.6B | $4.8B | $3.3B | $3.0B | $3.6B | $1.1B | ($4.5B) | $900M | $34M | $67M | $5.2B | $2.3B | $1.5B | $1.3B | $1.3B | $1.4B | $1.1B | $1.3B | $823M | $990M | $963M |
| Nettomarge % | 1.1% | 1.2% | 0.9% | 1.0% | 1.3% | 0.4% | -1.9% | 0.4% | 0.0% | 0.0% | 2.6% | 1.2% | 0.8% | 0.9% | 1.1% | 1.1% | 1.0% | 1.2% | 0.8% | 1.0% | 1.0% |
| EBITDA | — | $7.2B | $5.3B | $4.7B | $5.7B | $3.1B | ($3.6B) | $2.3B | $1.8B | $1.5B | $8.1B | $4.5B | $4.0B | $3.1B | $2.7B | $2.7B | $2.3B | $2.5B | $1.6B | $2.0B | $1.7B |
| Ergebnis je Aktie (EPS) | $37.37 | $38.37 | $25.72 | $22.39 | $25.04 | $7.23 | $-28.26 | $4.95 | $0.17 | $0.32 | $23.24 | $9.69 | $6.28 | $5.42 | $5.60 | $5.59 | $4.30 | $4.63 | $2.95 | $3.32 | $3.16 |
| Ausstehende Aktien (Mio.) | — | 124M | 128M | 134M | 142M | 154M | 161M | 182M | 197M | 209M | 223M | 233M | 235M | 233M | 239M | 251M | 263M | 273M | 279M | 298M | 305M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für MCK. /companies/us/MCK
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms